The aMoon team is a unique combination of scientists, clinicians, hi-tech pioneers and financial experts who are passionate about the healthtech revolution.
The team's international ventures background and unique interdisciplinary skills are key factors in building effective collaboration within global hubs. These relationships generate a vast network of exclusive opportunities and deal flow, providing deep value for our partners.
aMoon is a fusion of healthtech & life science specialists, hi-tech pioneers and financial experts who are passionate about healthtech revolution.
The team's international ventures background and unique interdisciplinary skills are key factors in building effective collaboration within global hubs. These relationships generate a vast network of exclusive opportunities and deal flow, providing deep value for our partners.
Yair Schindel, M.D.
Yair is the Co-Founder and Managing Partner of aMoon.
Previously, Yair served as the founding CEO of the State of Israel’s National Digital Bureau, responsible for digitizing governmental services and stimulating economic growth.
Yair is the founder of the MAOZ Network, an NGO building collaboration between Israel’s most influential leaders, with over 300 alumni dedicated to building collaboration between the private, social and public sectors.
Yair was an executive, investor, board or advisory board member in several healthcare startups including OmniGuide, Zebra Medical Vision, and Medisafe.
Yair earned his BSc and MD degrees at Ben-Gurion University and his MBA at Harvard Business School. He served in the IDF for five years and graduated as Chief Medical Officer for the Israeli Navy Seals, known as “Shayetet 13”.
Marius is an Anchor Investor at aMoon. In 1993, Marius co-founded Check Point Software Technologies Ltd. (NASDAQ:CHKP), a global pioneer of cybersecurity and the largest company in Israel. He is considered one of the founding fathers of Israel’s global cybersecurity industry.
Marius holds a BSc, cum laude, in Physics and Mathematics, from the Hebrew University, and an MSc in Electrical Engineering and Communications Systems from Tel Aviv University. He is a graduate of the IDF elite Talpiyot technological academy.
Tomer Berkovitz, PhD
Tomer is a Partner & CFO at aMoon, where he leads mid-late stage investments in healthtech companies. Tomer joined aMoon in early 2018 and led several investments including $30M Series C round in Zebra Medical Vision and $55M Series D round in Seer. He is also a board member in PharmaTwoB and Mapi. With 15 years of US capital markets experience, Tomer spearheads aMoon’s Bridge to Wall Street, where he manages the fund’s relationships with major investment banks, equity research analysts and investment funds.
Prior to joining aMoon, Tomer was the CFO & COO of Alcobra, a NASDAQ-listed development-stage biotech company, where he led successful public equity offerings from leading US healthcare funds. Prior to joining Alcobra, he was an Executive Director in J.P. Morgan’s Investment Banking Division in New York, where he played a leading role in numerous capital market and mergers and acquisitions transactions. In this capacity, he advised senior management and boards of directors of J.P. Morgan's key U.S. clients, including several S&P 500 healthcare firms. Prior to joining J.P. Morgan, Tomer worked in Citigroup's Investment Bank in New York. From 2000 to 2003, he served as an economist in the Financial Advisory Unit to the Chief of Staff of the Israel Defense Forces.
Tomer holds a Ph.D. in Finance and Economics (with Distinction) from Columbia Business School and has published a number of corporate finance articles in leading academic and practitioner journals. He also holds an M.Sc. in Finance and Accounting (Magna Cum Laude) and a B.A. in Economics and Management (Magna Cum Laude), both from Tel-Aviv University.
Todd is a Partner at aMoon and has over 15 years of healthcare investment experience. Prior to joining aMoon, he was a Managing Director at Signet Healthcare Partners, a NYC-based investment fund that provides growth capital to commercial stage life-science companies. Todd has served on the boards of Arbor Pharmaceuticals (Sold to KKR), Apicore (Sold to Medicure), Impopharma, and Smart Medical Systems. He also helped oversee the investment in Claris Lifesciences (sold to Baxter).
Prior to joining Signet, Todd was an Investment Director at Joddes Limited, a family investment holding company with interests in a number of healthcare companies, including Pharmascience, Paladin Labs, Medicom, and Oral Science. He was previously a large-cap pharmaceutical analyst at Morgan Stanley. He started his career at Mercer Management Consulting serving clients across North America in the transportation and healthcare industries.
Todd received a B.Com (with High Distinction) from the University of Toronto and an MBA from The Wharton School at the University of Pennsylvania with concentrations in healthcare management and finance.
Isaac is a Partner at aMoon. After beginning his career as an M&A specialist in investment banking at Credit Suisse First Boston in NY, London and Tokyo, Isaac spent over 20 years in Venture Capital and Private Equity.
Prior to joining aMoon, he was Senior Advisor to Permira in the purchase of Netafim (bought for $850M, sold at $1.9B) and to XIO in the purchase of Lumenis (bought for $512M, sold at $1.2B). Previously, he managed the $156M Renaissance Fund and set up the $50M Israel Intl’ Fund.
Isaac is a co-founder of Atudot Le'Israel, a national initiative of 25 talent management programs. He served as an active advisor to the Israeli government in numerous capacities such as The Committee for Corporate Governance, and a variety of committees that improved the allocation of capital for the private sector; the government and the public sector, while decreasing systemic risk.
He is the founding Chairman of both the Wharton and Harvard Business School Clubs of Israel.
Isaac served as an officer in the Artillery Corps of the IDF. He holds a Bachelors summa cum laude from Wharton and MBA from Harvard University.
Moshe Mor is a Partner at aMoon. Prior to aMoon, Moshe spent 19 years with Greylock Partners, a prominent global VC firm. Moshe first joined Greylock as a General Partner in 2001 at their Silicon Valley office. In 2006, Moshe moved back to Israel to co-found Greylock Israel (now 83North). From 2012 to 2019, he was a venture partner with the firm while spending a significant part of his time on social and philanthropic projects.
Before joining Greylock, Moshe was a hi-tech entrepreneur. He co-founded SPL WorldGroup and led it as its CEO from 1995 to 2000; overseeing a rapid global expansion and growing the company to 1,000 employees. SPL WorldGroup was acquired by Oracle (NASDAQ:ORCL) in 2003.
Moshe serves as a board member of CET (MATAH), a not-for-profit that is the leading provider of education technology in Israel, and is the Chairman of MindCET, its EdTech accelerator. Moshe is also the chairman of the ‘National Lay Leadership Team’, an initiative with the JDC’s Institute for Leadership & Governance that aims to recruit leaders from the business and public sectors to serve on NGO boards.
Moshe holds a BS degree in Economics from Tel Aviv University and an MBA from Harvard Business School, where he was a Baker Scholar. He served six years in the Israeli Army as a Captain in the Military Intelligence branch.
Michal Goren Miller
Michal is the Chief Legal & Compliance Officer at aMoon. She was the former deputy CEO and Legal Chief of the National Digital Bureau in the Prime Minister’s Office.
Previously, Michal was a member of the U-Bank Ltd's Board of Directors and Head of the Personal Banking Division, responsible for managing branches; the investment advisory unit; and acting as chairperson of the divisional credit committee. Additionally, Michal was in charge of U-Bank Trust Company Ltd., a subsidiary of the First International Bank Of Israel (FIBI), providing trust services on behalf the FIBI group to the capital markets. Before joining the FIBI group, Michal served for 12 years as Legal Advisor at Bank Hapoalim’s Commercial Division, Special Credit Unit.
Michal also served as a member of both the Board of Directors and the Investment Committee at K.H.R. Study Funds Ltd., on behalf of the State of Israel.
Yaron Daniely, PhD
Dr. Yaron Daniely is the Head of aMoon Alpha, an internal aMoon unit charged with maximizing the fund's unique scale and talent capabilities to achieve excess returns through portfolio success. Before joining aMoon, Dr. Daniely was President & CEO of Yissum, the Hebrew University's renowned Technology Transfer Company, and the co-chairperson of the Israel Technology Transfer Network – ITTN. Before joining Yissum in 2017, he served for eight years as President, CEO and Chairman of Alcobra Ltd (NASDAQ: ADHD). Prior to his appointment at Alcobra, Yaron held a number of leadership positions, including President and CEO of NanoCyte Inc., General Manager and VP of Business Development at Gamida Cell Ltd (NASDAQ:GMDA), and co-founder and Director of Bioblast Ltd. (NASADQ:ORPN).
Yaron earned his PhD from the Sackler Institute of Graduate Biomedical Sciences at the NYU School of Medicine. Following his doctoral program, Yaron served as a Visiting Fellow at the NIH, and as an American Cancer Society Postdoctoral Fellow in the Department of Molecular Cell Biology at The Weizmann Institute for Science in Israel. Yaron also holds an MBA degree from the Technion-Israel Institute of Technology.
Dorit is a Managing Director at aMoon. She is a medical technology executive with extensive experience in Innovation, Investments, Business Development and Strategy.
Dorit previously worked with Amgen, scouting globally for new platforms, technologies and open innovation capabilities with a focus on digital health, diagnostics, drug formulations, and devices.
Before Amgen, Dorit co-founded Sanara Ventures (Philips Healthcare and Teva Pharmaceuticals Joint Technology Incubator), worked as a Principal with Evergreen Venture Partners, focusing on Life Sciences investments in Israel and held VP Business Development positions with few medical technology startups (e.g., ColBar LifeScience which was acquired by J&J).
Previously, she worked as a consultant with McKinsey & company's Pharmaceutical & Medical Products Practice in the US and Israel.
Dorit is a pharmacist with a B.Pharm degree from the Hebrew University of Jerusalem and an MBA from Kellogg School of Management, Northwestern University.
Gur Roshwalb, MD
Gur Roshwalb, MD, MBA, is a Managing Director at aMoon with over 20 years of healthcare industry and finance experience. Prior to joining aMoon, he was CEO at several private and public biotech companies. Before moving to industry, Gur was a Vice President at Venrock, where he was an investment professional on the healthcare team investing in both private and public companies. Gur started his finance career at Piper Jaffray, where he worked as a vice president and equity analyst, publishing research on specialty pharmaceutical companies. Prior to Piper, Gur was in private practice in New York following residency training in internal medicine at Mount Sinai Medical Center, where he served as Chief Resident. Gur obtained his medical degree from Albert Einstein College of Medicine of Yeshiva University, his MBA from the NYU Stern School of Business and a B.A. from Columbia University.
Roy is a Managing Director at aMoon. He has nearly 15 years of investment experience, first as an M&A and Private Equity lawyer in New York, Hong Kong and Tel Aviv, and later as a venture capitalist.
Before joining aMoon, Roy was the CEO of Hutchison Kinrot, a global leading incubator and seed investor in water technologies & Cleantech, owned by Hong Kong conglomerate CK Hutchison Holdings. He led numerous investments in early stage Israeli start-ups, serving on the boards of all portfolio companies and guiding them from technological concept to early commercialization. Prior to that he was a Partner at the International M&A and Capital Markets department of a leading Israeli law firm, also heading its international private equity practice.
Roy spent nearly five years with international law firm Weil Gotshal, working on complex M&A and Private Equity transactions, and was a member of the founding team of the firm's Hong Kong office.
He holds an LLB from the Hebrew University of Jerusalem, and dual MPA (Public & Economic Policy) from the London School of Economics and Columbia University. He is a certified lawyer in Israel and New York.
Nurit Tweezer Zaks, MD, MBA
Nurit is an Head of Sourcing at aMoon. She brings to aMoon 12 years of experience with Sanofi, initially as Medical Director of Sanofi Israel and then as a Senior Director at Sanofi’s Global R&D arm for External Innovation & Scouting. Nurit was also the Medical Lead at Sanofi for Global Established Products and Strategic Portfolio Enhancement.
Prior to Sanofi, Nurit served over a decade as Senior Physician at Sheba Medical Center and Maccabi Health Services as a Specialist in Internal Medicine and Rheumatology, and as a Clinical and Research fellow at the National Institutes of Health (NIH) in Bethesda, Maryland.
Nurit was granted Outstanding Lecturer at the Tel Aviv University and is experienced as an international speaker both at Academic Conferences and Industry related meetings.
She sits on the Board of Directors and Advisory Boards for several Healthcare startups and Organizations.
Nurit earned her BSc and MD degrees at Ben Gurion University and her MBA at Kellogg Business School and the Tel Aviv University.
Brachie Sprung is the Vice President of Investor Relations & Communications at aMoon. Before joining aMoon she was the Director of the International Office of Jerusalem Partnerships, an initiative spearheaded by the Mayor of Jerusalem and philanthropic global foundations focused on building private public partnerships for the city of Jerusalem. Previously Brachie was the Senior Advisor for International Affairs and Media to the Mayor of Jerusalem. In this capacity, she was responsible for developing strategy, building partnerships and setting priorities for all aspects of international engagement and media. Prior to joining the Mayor's team, Brachie served as Associate Director of PresenTense. She helped organize and hosted TEDx Jerusalem in 2012 and co-created the Magid Project, a Schusterman Connection Point.
Irena Katsman, CPA
Irena is the Vice President of Finance at aMoon and has over 12 years of finance management experience in public companies and business units of global enterprises.
Prior to joining aMoon, Irena was the VP Finance of Alcobra (NASDAQ: ADHD) a development-stage biotech company where she led the financial aspects of Alcobra’s operations and has played a key role in Public equity offering and Alcobra’s merger with Arcturus Therapeutics (NASDAQ: ARCT), a San-Diego based mRNA company.
Prior to joining Alcobra, she was Finance Manager at Omrix Biopharmaceuticals, a Johnson &Johnson company.
Irena began her career as a Senior Associate in the high-tech cluster at PwC Israel.
Irena is a Certified Public Accountant and holds a B.A. in Economics and Accounting from the Hebrew University of Jerusalem and an M.B.A. from Tel Aviv University.
Eran is a Principal at aMoon. He brings a strong business development, marketing and sales background in Medical Devices, Pharmaceuticals, Digital Health, Diagnostics, and Medical Nutrition from his 9 years at Abbott, where he held increasingly senior roles in the organization, both in Israel and in the US. In his last role, he was part of Abbott Israel Management Team, and led one of the company’s business units with full P&L responsibility. Eran developed and executed franchise strategy to grow the business and was awarded several global Excellence Awards. Also, he scouted and evaluated technologies in various medical fields suitable for Abbott’s global strategy, leading to agreements with strategic partners
Eran joined Abbott as a member of its corporate Management Development Program, a three-year global rotational program for top tier MBAs, aiming to develop the company’s future leaders.
Prior to Abbott, Eran worked at Johnson and Johnson in medical device sales and at Evogene in R&D and Business Development.
Eran earned his B.Sc. in Biotechnology Engineering from Ben-Gurion University and his MBA from the University of Michigan, Ross School of Business.
Omri is a Principal at aMoon. Prior to joining aMoon, Omri worked as an investment professional at Apax Partners, where he worked on a number of transactions and portfolio companies. Omri was also an investment banker with Bank of America Merrill Lynch in New York and London, where he specialized in advising corporate clients on mergers and acquisitions and capital markets transactions.
Omri holds a BA, with High Honors, in Economics and Psychology from Brandeis University.
Reut Shema, PhD
Reut is a Principal at aMoon. Previously, Reut was an Associate at aMoon, and prior to that VP Business development and scientific advisor at greenfield partners, a TPG growth investment platform. She also served as an advisor to several prominent international investors and co-founded a company in the healthcare field.
Reut has over 10 years of experience in cutting edge research and has won numerous grants and awards for her work. She was a postdoctoral fellow at the Broad Institute of MIT and Harvard, where she led a project team to develop a novel platform for evaluating therapeutics for psychiatric diseases. Her study of ageing and neurodegenerative disease has led to the development of a novel in vivo screening method and was published in the high impact journal PNAS.
Reut completed her PhD in Weizmann Institute of Science, where she studied Long term memory maintenance in the brain. Her work has contributed greatly to the field and is summarized in three papers, including two in the prestigious journal Science. She holds a B.Sc. in Biology and psychology (Magna Cum Laude) from Tel-Aviv University
Daniel E. Cohen
Daniel is the Director of Research for aMoon Alpha. Previously, he worked as an Investment Banker in New York, advising on mergers and acquisitions, equity and debt capital raising, and royalty monetizations in the healthcare industry. While at MTS Health Partners, Daniel closely served on the deal teams advising clients such as Otsuka Pharmaceutical, Horizon Pharma, and Caladrius Biosciences, for a total deal volume of ~$2 billion. He also worked as a Senior Analyst at Lazard Frères & Co., advising corporate clients on special situations, including a healthcare services company in an activist investor campaign.
Daniel earned his BA in Financial Economics from Columbia University, where he focused on Biopharmaceutical Development & Regulation.
Elinor Belkine Michaeli
Elinor is aMoon's Director of Operations. She brings to aMoon more than 20 years of experience in the senior management environment of large organizations, in both public and business sectors, including the role of Head of Staff of Coca-Cola Israel Group and other leading positions in Coca-Cola and the IBA (Israel Broadcasting Authority).
She also served as Head of Foreign Relations and Director of Operations to the IDF attaché at the Israel Embassy in Paris. Elinor holds a BA, cum laude, in International Relations and Social Sciences from The Hebrew University of Jerusalem and served as an officer in the IDF’s prestigious Unit 8200.
Hila Oved, CPA
Hila is aMoon's Director of Finance, bringing with her more than a decade of finance effectual experience, proficient in the field of private equity and venture capital funds.
Prior to joining aMoon, Hila was a senior manager in Ernst & Young (EY), where she played a leading role in managing the accounts of major investment funds, publicly-traded and privately held high-tech and biotech entities.
In this capacity, she gained extensive experience in financial statements analysis and taxation of funds and companies. She also advised clients during merger and acquisitions and conducted and led teams in execution of financial and tax due-diligence.
Hila is a Certified Public Accountant (CPA) and holds a BA in Economic and Business Administration (Magna Cum Laude) from Bar-Ilan University and an MBA from Tel-Aviv University with concentration in financial management.
Yael is aMoon’s Director of Portfolio Analysis, bringing with her 8 years of finance management experience in private companies, public companies and business units of global corporates.
Prior to joining aMoon, Yael was a senior controller in Magic Leap Israel ltd. an R&D unit of US based corporate, where she was a head of Accounting department, overseeing the implementation of various financial systems and building efficient financial structure of the Israeli site.
Prior to joining Magic Leap, she was a controller at Brook Keret, Israel top 2 financial service provider, in this capacity, she gained vast experience in financial management.
Yael began her career as a Senior Associate at Ernst & Young Israel.
Yael is a Certified Public Accountant and holds a B.A. in Accounting and Business Administration from the College of Management, Israel.
Noam is Senior Legal Counsel at aMoon and has been practicing law for over 10 years. He was most recently special counsel at Amit, Pollak, Matalon & Co., and previously worked at Meitar Liquonik Geva Leshem Tal in Tel Aviv and Debevoise & Plimpton in New York. Noam has wide experience in corporate legal affairs, including mergers and acquisitions, venture capital investing, joint ventures and the formation and maintenance of venture capital and other private equity funds. He has also worked with many startups as they attempt to grow their companies, advising startups regarding investment rounds, commercial agreements and day-to-day operations. Noam obtained his JD from New York University School of Law and his BA from Yale University. Noam was admitted to practice law in New York in 2009 and Israel in 2014.
Alon is an Associate at aMoon. Prior to joining aMoon, Alon was an Investment Banker with Citi, advising on M&A and capital markets transactions across a variety of sectors. Alon also worked as a Financial Consultant at Cognum (Formerly Itzhak Swary & Co.), where he provided financial advisory services to corporate clients on valuation, commercial due diligence, and construction of business plans. Alon holds a BA (Magna Cum Laude) in Economics and Accounting from the Hebrew University of Jerusalem.
Victoria Balannik, PhD
Victoria is an Associate at aMoon. She is a multidisciplinary biomedical professional with extensive expertise in healthcare innovation.
Prior to joining aMoon, Victoria worked as a Director of Business Development in BiolineRX, where she performed global scouting and led scientific and commercial evaluation of novel therapeutics.
Previously Victoria worked as a Research Scientist for Amazon and as a Drug Development Manager for Influmedix.
Victoria conducted her Postdoctoral Research at the department of Neurobiology at Northwestern University and earned her PhD in Neuroscience from the Hebrew University School of Medicine.
Yifat Segev, PhD
Yifat is an Associate at aMoon. She earned her PhD from the Department of Neurobiology at Haifa University, where she specialized in neuroscience, focusing on biochemical pathways of learning and memory in Alzheimer's disease. Her work ultimately led to a patent and a spinout company via the Carmel Ltd., Technology Transfer Organization.
Yifat’s MSc is from the Weizmann Institute, where she specialized in Neuroimmunology. She earned her BSc from the Technion-Israel Institute of Technology, which included study at Carnegie Mellon University. She has published numerous scientific papers, including in Neurobiology of Aging and the Journal of Neuroscience, and she has been cited in a number of innovative papers.
Moria Kwiat, PhD
Moria is an Analyst at aMoon. Formerly, she was an analyst at Frost & Sullivan, leading their Israeli Health Care division. Moria is a board member at Pluristem Therapeutics Inc., and was a research associate in the Center for Nanoscience and Nanotechnology at Tel Aviv University. A specialist in the field of biotechnology with a strong track record of developing biosensors for diagnostics utilizing electrical devices, Moria has published numerous scientific papers.
Moria holds a Ph.D. and Postdoc in Nano-Biotechnology from Tel Aviv University, and a M.Sc. Magna Cum Laude in Biotechnology from Tel Aviv University.
Tamar Farfel-Becker, PhD
Tamar is an Analyst at aMoon. She is an accomplished neurobiologist with over 10 years of experience in cutting-edge research of mouse and cell models. Prior to joining aMoon, Tamar was a postdoctoral fellow at the National Institutes of Health (NIH) in Bethesda, Maryland, where she studied lysosome trafficking and function in neurons in health and CNS diseases.
Tamar completed her PhD at the Weizmann Institute of Science, studying the neuropathology of Gaucher disease, a rare genetic disorder. She published many articles in high impact scientific journals including Cell Reports, Trends in Neuroscience, Human Molecular Genetics and Nature Medicine.
Tamar obtained her BSc in Biology and Psychology (Summa Cum Laude) from the Tel-Aviv University. She served as an officer at the IDF’s elite technological unit 8200.
Tamir is an Analyst at aMoon. Prior to aMoon Tamir worked as a student intern at the State's Attorney Financial and Fiscal department. Tamir served as a captain in the Israeli navy seals, Shayetet 13, and continues to serve as such in reserve service. Tamir holds an LLB and an MA in Financial Economics (with honors) from the IDC, Hertzliya.
Shiran is the Operations and Special Projects Manager at aMoon. She holds a BA and MA in Political Science, from the Hebrew University in Jerusalem. Shiran previously worked as the Senior Office Manager at the government’s National Digital Bureau, of the Prime Minister's Office.
Hila Yarom Roytman
Hila Yarom Roytman is the Storytelling and Marketing Manager at aMoon. Before joining aMoon, she served as a Spokesperson and Director of Digital Diplomacy in the Permanent Mission of Israel to the United Nations. Previously, Hila served as a captain in the IDF Spokesperson Unit, where she held various senior media and public relations positions. In her most recent role, she led the IDF’s press relations with online media outlets and radio stations.
Hila holds an MPA from New York University, and a BA in Social Sciences from Bar-Ilan University.
Katie is a Project Manager for the Investor Relations team at aMoon. Previously Katie worked as a Data Analyst at Kantar Millward Brown, as part of a specialized team that designed customized market research and consulting solutions for Fortune 500 companies. Prior to Kantar Millward Brown, Katie was a Research Assistant at the University of Rochester, assisting with a range of studies on how chroma impacts impression formation in zero-acquaintance situations.
Katie has also spent an extended amount of time living and working in Puerto Rico, to help rebuild the island in the wake of the devastation caused by Hurricane Maria.
Katie holds a BA from the University of Rochester with a dual major in Brain and Cognitive Science and Psychology, and a Credential of Readiness (CORe) from Harvard Business School Online.
Dasha Genasia, MBADasha is HR Manager at aMoon. Previously she worked as a HR professional in Australia. Dasha has extensive experience in compensation & benefits, performance management, HR project management and providing generalist HR support and advice to multiple business units.Dasha holds a Bachelor of Business specializing in Human Resources and Honours Degree of Bachelor of Commerce specializing in Management from Monash University and Master of Business Administration (MBA) specializing in Strategic Human Resources Management from Haifa University.
Yafit is a Bookkeeper at aMoon, bringing with her 20 years of experience in the field. Prior to working at aMoon, Yafit worked as an independent bookeeper for Cellcom Israel Ltd. in the finance department, and at Gas Technologies & Chemicals Ltd.
Yafit has completed tax studies at the Tel Aviv College of Management.
Diamanta Edgar Ronen
Diamanta is the Personal Assistant to the Managing Directors at aMoon. She holds a BA in Communications and Management from The College of Management.
Prior to working at aMoon, Diamanta worked as Sales & Customer Relations Manager at Spartex Ltd. Diamanta also worked as PA to the CEO at Citi (Citibank N.A.) and McKinsey & Company.
Lilach is the Personal Assistant to Dr. Yaron Daniely, Head of aMoon Alpha, an internal aMoon unit charged with maximizing the fund’s unique scale and talent capabilities to achieve excess returns through portfolio success.
Before joining aMoon, Lilach was the EA to Co-Founder and CEO at DayTwo. Prior to DayTwo, she served 17 years at Teva Pharmaceutical as an EA and Project Manager.
She holds a BA in Behavioral Sciences from the Open University.
Rebecca is a Personal Assistant to the Partners at aMoon. She holds a BA from the Hebrew University of Jerusalem and is a certified English teacher. Rebecca previously worked as Senior Coordinator of the Development, Donor and Events Dept. at Hadassah Hospital in Jerusalem.
Uri is an intern at aMoon. He is a Third-year student in an excellence program for Accounting and Law at Tel Aviv University. Previously to working at aMoon, Uri worked as a Regional Manager at "Who Dares Wins" – a youth educational sports movement.
Uri served as a captain in the Israeli navy seals – Shayetet 13 - and continues to serve as such in reserve duty.